Lung cancer epigenetic diagnostic kits
SHOX2 & PTGER Epi proLung® lung cancer detection test
Epi proLung® lung cancer detection test
Sensitivity, % 78
Specificity, % 96
Epi proLung® - liquid blood-based biopsy test for lung cancer detection from DNA extracted from plasma. Diagnosing lung cancer remains
challenging and represents a highly unmet medical need. Lung cancer risk factors include patient life history, and/or presentation with symptoms, and/or radiological findings in the
lung.
Radiological screening methods suffer from a high false positivity rate and therefore complementary confirmatory diagnostic methods are
urgently needed. A reflex test that clarifies indeterminate findings will aid in earlier identification of illness, improved outcomes, and lower costs of treatment by reducing unnecessary
procedures.
- Epi proLung® is based on a combination of proprietary Epigenomics DNA methylation biomarkers SHOX2 and PTGER4. The product has received CE-IVD mark in Europe.
- Clinical performance was assessed in a validation study comprising data from clinical specimens from consented patients enrolled at sites in the US and Europe. The epigenetic diagnostics test discriminates malignant from non-malignant disease with AUC = 0,73.
- Test results should be ordered and interpreted by a healthcare professional.
0,00 €
incl. VAT and free shipping to selected countries
Free shipping to the following countries: Germany
- Sold Out
Lung EpiCheck lung cancer blood test
Lung EpiCheck is a simple blood test that detects lung tumor DNA circulating in the blood. The test detects subtle disease-specific changes in DNA methylation markers. Lung EpiCheck is an objective molecular test meaning that it does not rely on human interpretation. The result is a clear positive/negative result, with an additional numerical result between 0-100.
EarlyTect® PCDHGA12 lung cancer detection in pulmonary nodule patients
Qualitative detection of epigenetic markers associated with lung cancer in pulmonary nodule patients.
Blood-based epigenetic biomarker PCDHGA12 test with proven clinical sensitivity and specificity for lung cancer. It has been proven to be able to diagnose lung cancer with 77.8% sensitivity and specificity of 92.3% in a pivotal study on 522 subjects. It utilizes the general real time PCR Instrument Systems to measure epigenetic marker in 2 ml of serum samples. This easy to use and fast solution requires less than 8 h of hands-on time, providing actionable results in real-time.
